725 related articles for article (PubMed ID: 30910896)
1.
Nishimoto AT; Wiederhold NP; Flowers SA; Zhang Q; Kelly SL; Morschhäuser J; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910896
[TBL] [Abstract][Full Text] [Related]
2. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
3. The Evolution of Azole Resistance in
Warrilow AG; Nishimoto AT; Parker JE; Price CL; Flowers SA; Kelly DE; Rogers PD; Kelly SL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30783005
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161.
Nishimoto AT; Whaley SG; Wiederhold NP; Zhang Q; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383660
[TBL] [Abstract][Full Text] [Related]
5. Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.
Monk BC; Keniya MV; Sabherwal M; Wilson RK; Graham DO; Hassan HF; Chen D; Tyndall JDA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397057
[TBL] [Abstract][Full Text] [Related]
6. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
[TBL] [Abstract][Full Text] [Related]
7. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
[TBL] [Abstract][Full Text] [Related]
8. The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.
Warrilow AGS; Parker JE; Price CL; Garvey EP; Hoekstra WJ; Schotzinger RJ; Wiederhold NP; Nes WD; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483956
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of the tetrazole VT-1161 compared with itraconazole and fluconazole against
Wang L; Zhang M; Guo J; Guo W; Zhong N; Shen H; Cai J; Zhu Z; Wu W
Mycologia; 2021; 113(5):918-925. PubMed ID: 34132632
[TBL] [Abstract][Full Text] [Related]
10. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.
Break TJ; Desai JV; Natarajan M; Ferre EMN; Henderson C; Zelazny AM; Siebenlist U; Hoekstra WJ; Schotzinger RJ; Garvey EP; Lionakis MS
J Antimicrob Chemother; 2018 Jan; 73(1):151-155. PubMed ID: 29040636
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
12. Upc2-mediated mechanisms of azole resistance in
Li J; Aubry L; Brandalise D; Coste AT; Sanglard D; Lamoth F
Microbiol Spectr; 2024 Feb; 12(2):e0352623. PubMed ID: 38206035
[No Abstract] [Full Text] [Related]
13. Molecular Mechanisms of Azole Resistance in Four Clinical
Shi H; Zhang Y; Zhang M; Chang W; Lou H
Microb Drug Resist; 2021 Dec; 27(12):1641-1651. PubMed ID: 34037478
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and
Nishimoto AT; Zhang Q; Hazlett B; Morschhäuser J; Rogers PD
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833425
[TBL] [Abstract][Full Text] [Related]
15. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.
Flowers SA; Colón B; Whaley SG; Schuler MA; Rogers PD
Antimicrob Agents Chemother; 2015 Jan; 59(1):450-60. PubMed ID: 25385095
[TBL] [Abstract][Full Text] [Related]
16. Delineation of the Direct Contribution of Candida auris
Rybak JM; Sharma C; Doorley LA; Barker KS; Palmer GE; Rogers PD
Microbiol Spectr; 2021 Dec; 9(3):e0158521. PubMed ID: 34878305
[TBL] [Abstract][Full Text] [Related]
17. VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice.
Break TJ; Desai JV; Healey KR; Natarajan M; Ferre EMN; Henderson C; Zelazny A; Siebenlist U; Yates CM; Cohen OJ; Schotzinger RJ; Perlin DS; Garvey EP; Lionakis MS
J Antimicrob Chemother; 2018 Aug; 73(8):2089-2094. PubMed ID: 29788070
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China.
Liu JY; Shi C; Wang Y; Li WJ; Zhao Y; Xiang MJ
Res Microbiol; 2015 Apr; 166(3):153-61. PubMed ID: 25748216
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates.
Strzelczyk JK; Slemp-Migiel A; Rother M; Gołąbek K; Wiczkowski A
Acta Biochim Pol; 2013; 60(4):547-52. PubMed ID: 24340302
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Eddouzi J; Parker JE; Vale-Silva LA; Coste A; Ischer F; Kelly S; Manai M; Sanglard D
Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
